Drug Management in Heart Failure

ConditionHeart Failure
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorIRCCS San Raffaele Roma

About this trial

Aim of the proposal is to create an interactive AI-based multicentre prospective database to provide information on how to improve the QoC for pts with HF.This will provide detailed information on pts characteristics,treatment practices, adherence to prescribed guideline-based optimal drug therapy,and outcomes.The database stems from a registry started two years ago,conceived to provide a contemporary snapshot on the adherence to the latest European GGLL for the therapeutic management of pts with HF.The database will be integrated with a specifically designed algorithm that provides an accurate feedback on whether patients are properly treated according to the ESC most recent recommendations.The expected outcomes are:-define non-adherence level to GGLL-based recommendations for treatment of HF;-provide information on initiation, adherence and persistence over time of the recommended treatment;-reduce medical inertia;produce practical implications to reduce morbidity and mortality

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Both gender

Age >18 years

Signed informed consent for the study

Known diagnosis of heart failure > 6 months

Disqualifiers

Conditions that, in the investigator's judgment, may interfere with the study or contraindicate participation for safety reasons

Concurrent diagnosis of neoplasia

Advanced COPD (FEV1 <50%)

Advanced valvular heart disease (severe mitral-aortic stenosis-insufficiency requiring cardiac surgery)

Trial population

Patients with heart Failure

Trial design

Design model

Other

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

create a registry that provides an updated assessment of the pattern of use of treatments recommended by guidelines in order to collect new evidence on compliance with them. Be they European or Italian for the treatment of patients with increased cardiov

Time frame
from enrollment to the end of observation al 24 months

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

IRCCS San Raffaele Roma

Lead sponsor

Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari

Collaborator

Azienda Ospedaliera Universitaria Mater Domini, Catanzaro

Collaborator